WitrynaOur Research Papers and Publications. Kumar C, Kohli S, Chiliveru S, Jain M, Sharan B* (2024). Complete remission of rare adenocarcinoma of the oropharynx with APCEDEN® (dendritic cell-based vaccine): a case report. Clinical Case Reports 5 (10):1692-1696. WitrynaThe goal of our study was to determine whether CD22 could become an alternative target for CAR-NK-92 therapy against B cell lymphoma. We first generated m971-BBZ NK-92 that expressed a CAR for binding CD22 in vitro. The expression of CAR was assessed by flow cytometric analysis as well as immunoblotting. The cytotoxicity of the m971-BBZ …
National Center for Biotechnology Information
Witryna1 dzień temu · Cancer Immunology, Immunotherapy. Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is … WitrynaFind the latest published documents for immunotherapy target, Related hot topics, top authors, the most cited documents, and related journals gps wilhelmshaven personalabteilung
Phenotypic plasticity and reduced tissue retention of exhausted …
Witryna10 kwi 2024 · Research led by scientists at UCLA Jonsson Comprehensive Cancer Center found that responses to a type of immunotherapy called PD-1 checkpoint blockade in patients with advanced melanoma depended ... WitrynaIntroduction. Cell-based immunotherapy uses a cell type from the immune system as therapeutic agent. For this purpose, the cells are first removed from the body, then activated or modified, expanded and finally re-infused into the patient. These are some of the strategies currently being investigated: Adoptive T cell therapy focuses on ... Witryna14 kwi 2024 · In order to determine the benefit of combining these drugs in patients with advanced clear cell renal cell carcinoma, Choueiri and colleagues conducted a phase II clinical trial to evaluate the activity and safety of belzutifan plus cabozantinib in 117 patients with advanced clear cell renal cell carcinoma that is either treatment-naive … gps wilhelmshaven